Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat
https://www.zacks.com/stock/news/2236096/nektar-nktr-q4-loss-wider-than-expected-revenue-beat?cid=CS-ZC-FT-analyst_blog|earnings_article-2236096
Mar 05, 2024 - Nektar (NKTR) reports a wider-than-expected loss in the fourth quarter of 2023 while revenue beat estimates.
0
Should You Buy Red-Hot Stocks Now or Wait?
https://www.zacks.com/stock/news/2237396/should-you-buy-red-hot-stocks-now-or-wait?cid=CS-ZC-FT-market_edge-2237396
Mar 07, 2024 - After a mesmerizing rally to start 2024, is it too late to buy the hottest stocks?
0
Madrigal (MDGL) Stock Up as FDA Approves First Drug for NASH
https://www.zacks.com/stock/news/2241318/madrigal-mdgl-stock-up-as-fda-approves-first-drug-for-nash?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2241318
Mar 15, 2024 - Madrigal Pharmaceuticals' (MDGL) Rezdiffra (resmetirom) is the first and only medicine approved by the FDA for the treatment of NASH.
0
Wall Street Awaits Consumer Confidence Data
https://www.zacks.com/stock/news/2246106/wall-street-awaits-consumer-confidence-data?cid=CS-ZC-FT-economic_highlights-2246106
Mar 26, 2024 - Wall Street Awaits Consumer Confidence Data
0
Viking (VKTX) Up 17% on Encouraging Oral Obesity Drug Data
https://www.zacks.com/stock/news/2246931/viking-vktx-up-17-on-encouraging-oral-obesity-drug-data?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2246931
Mar 27, 2024 - Data from an early-stage study shows that patients who received Viking's (VKTX) orally-administered obesity drug lost up to 5.3% of their body weight after 28 days.
0
Eli Lilly (LLY) Stock Dips While Market Gains: Key Facts
https://www.zacks.com/stock/news/2256381/eli-lilly-lly-stock-dips-while-market-gains-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2256381
Apr 16, 2024 - In the closing of the recent trading day, Eli Lilly (LLY) stood at $749.26, denoting a -0.2% change from the preceding trading day.
0
Eli Lilly (LLY) Advances But Underperforms Market: Key Facts
https://www.zacks.com/stock/news/2259608/eli-lilly-lly-advances-but-underperforms-market-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2259608
Apr 22, 2024 - Eli Lilly (LLY) concluded the recent trading session at $731.33, signifying a +0.69% move from its prior day's close.
0
Annovis Bio (ANVS) Stock Surges 38% in a Month: Here's Why
https://www.zacks.com/stock/news/2192301/annovis-bio-anvs-stock-surges-38-in-a-month-here-s-why?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-2192301
Dec 01, 2023 - Annovis' (ANVS) shares surge on the successful development of its lead candidate in Alzheimer's disease.
0
Eli Lilly (LLY) Rises Higher Than Market: Key Facts
https://www.zacks.com/stock/news/2195769/eli-lilly-lly-rises-higher-than-market-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2195769
Dec 08, 2023 - The latest trading day saw Eli Lilly (LLY) settling at $598.05, representing a +1.66% change from its previous close.
0
LLY Down as Patients Regain Weight After Stopping Zepbound
https://www.zacks.com/stock/news/2196988/lly-down-as-patients-regain-weight-after-stopping-zepbound?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2196988
Dec 12, 2023 - Full results from a late-stage study show that patients who stopped taking Eli Lilly's (LLY) weight-loss drug for over a year slowly started to regain their lost weight.
0